Edition:
India

China NT Pharma Group Co Ltd (1011.HK)

1011.HK on Hong Kong Stock

2.10HKD
7:13am IST
Change (% chg)

HK$0.03 (+1.45%)
Prev Close
HK$2.07
Open
HK$2.07
Day's High
HK$2.10
Day's Low
HK$2.07
Volume
181,500
Avg. Vol
4,525,850
52-wk High
HK$2.48
52-wk Low
HK$1.61

Latest Key Developments (Source: Significant Developments)

China NT Pharma Group Co Appoints Wang Fei As CFO
Friday, 6 Apr 2018 

April 6 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::CHIU YU KANG RESIGNED AS CHIEF FINANCIAL OFFICER.‍APPOINTS WANG FEI AS CFO.  Full Article

China NT Pharma Group Co says HY profit attributable to equity shareholders up 61.1 pct
Monday, 21 Aug 2017 

Aug 21 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::HY profit attributable to equity shareholders of company increased by 61.1% from RMB50.1 million to RMB80.7 million.HY overall revenue of group up 44.9 percent to RMB559.1 million.  Full Article

China NT Pharma enters deal to issue 325 mln shares at HK$1.83 per share
Wednesday, 19 Apr 2017 

April 19 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>:Company entered into placing agreement.Co agreed to issue aggregate of 325 million convertible preference shares at a price of HK$1.83 per convertible preference shares.  Full Article

China NT Pharma says FY net profit RMB 116.2 mln
Wednesday, 22 Mar 2017 

China Nt Pharma Group Co Ltd <1011.HK>: Board recommended a final dividend of hk2.5 cents per share . Group reported a net profit of rmb116.2 million for year ended 31 december 2016, as compared with a net profit of rmb87.7 million .Overall revenue of the group for the year ended 31 december 2016 increased by rmb67.4 million or 7.9% to rmb915.1 million.  Full Article

China Nt Pharma obtains certification from China Food and Drug Administration
Friday, 3 Mar 2017 

China Nt Pharma Group Co Ltd <1011.HK>: Jiangsu NT Biopharma successfully obtained new good manufacturing practices certification from China Food and Drug Administration .Estimated that production line can commence production of "Xi Di Ke" in March and sales will officially commence in April.  Full Article

BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

* PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®